The Future Of Oncology At J&J: An Interview With William Hait
Executive Summary
The pharmaceuticals business is riding high at Johnson & Johnson, posting impressive gains from new launches in immunology and cancer – in particular, the May launch of Zytiga (abiraterone acetate) in the U.S. for metastatic castration-resistant prostate cancer.
You may also be interested in...
J&J’s Solid Launches Lead Strong Pharma Segment Quarter
Johnson & Johnson’s pharma unit posted strong sales growth in immunology and infectious disease, while its burgeoning oncology business is growing substantially.
J&J Highlights Late-Stage R&D Prospects Across Pharma Division
J&J says its success at integrating external and internal innovation, focus on understanding causes of disease and commercial excellence have helped its pharma subsidiary weather a $9 billion patent cliff and recoup growth prospects. One observation from its May 23 analyst meeting: seemingly more than most companies, Janssen systemically incorporates biomarkers and companion diagnostics beyond oncology into all of its core development programs.
Tackling Mechanisms Of Disease Resistance At Janssen
“We see the whole market really changing over the next 10 years to reflect more and more use of mechanisms other than anti-TNFs,” Sue Dillon says.